Tolerability of antiretroviral therapy (HAART) in elderly age by Celesia, B M
LECTURE PRESENTATION Open Access
Tolerability of antiretroviral therapy (HAART) in
elderly age
B M Celesia
From de Senectute: Age and Health Forum
Catanzaro, Italy. 5-7 December 2009
Background
The median age of people living with HIV/AIDS is
increasing: while efficacy of HAART has reduced mor-
tality and prolonged the life of patients, low perception
of risk and new late diagnosis are related to infection in
an elderly age. Most new late diagnosis are performed
in older hardly immuno-compromised subjects; the
development of opportunistic diseases complicates man-
agement of therapeutic strategies (drugs interactions,
cumulative toxicities, hypersensitivity reaction), mainly
in presence of comorbities.
Most randomized clinical trials with new drugs tend
to avoid the enrolment of >50 years patients with proper
comorbities of old age. So the few data we can analyze
come from observational cohorts.
While it is well defined that older people are more
adherent to treatment and achieved an adequate control
of HIV-RNA viremia more frequently than younger
although an incomplete immuno-reconstitution, the
development of drug toxicity with higher frequency is
controversial.
Elderly people are more frequent to show reduced
hepatic and kidney function, frequently have comorbities
requesting new therapies with a higher pill burden and
higher risk of drug interactions. Most antiretroviral
drugs are metabolized by cytochrome system. Treatment
may accelerate mitochondrial dysfunction, nucleoside
reverse transcriptase inhibitors may contribute to mus-
cle wasting. Some typical side effects of HAART such as
body change and facial lypoatrophy could be more evi-
dent when associated with natural facial changes occur-
ring with aging and modify negatively self perceived
body image and relationship capacity. Age was also
shown to increase the risk of renal tubular disease in
association with tenofovir.
Age is one of the major cardio-vascular disease (CVD)
risk factors and the inflammatory component may con-
tribute to this increased risk despite HAART efficacy.
The risk of myocardial infarctions is increased in older
treated HIV+ patients: metabolic abnormalities are more
frequent at baseline and the treatment could increase
the cumulative risk of CVD.
Conclusions
Tolerability of HAART seems do not differ in older vs
younger patients although new cardiovascular, endo-
crine, metabolic or neurological events are more prob-
able in the first group.
An increasing number of people older than 50 years
old will attend our clinics in the near future. It’ll be
necessary to monitor short and long term toxicity and
consider the different pharmacokinetics of drugs in an
older body to perform adequate therapeutic strategies
and to reduce risk of drugs interactions.
The care of patients with HIV will probably become
more complex and more specialists will called on to
help manage this complex disease.
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